As one of the leading scientists, what are Geng Meiyu s representative publications?

As of November 2019, Geng Meiyu has published more than 230 articles**, such as "Glycosylation of sialic acid N-phenyltrifluoroacetylimide ester and phenyl alkylate as donors", "Preclinical study of HSH-971, a new anti-Alzheimer's disease-like drug", etc.; In addition, Geng Meiyu has also supervised the studies of many master's and doctoral students, such as Jiang Shan's "Research on the Inhibitory Effect of Lung Cancer and Its Mechanism of Cat's Eye Active Ingredient Extract" in 2011.

Geng Meiyu's representative publications include "Research on the Glycosylation of Sialic Acid N-Phenyltrifluoroacetylimide and Phenylalkyne Esters as Donors" and "Preclinical Study of HSH-971, a New Anti-Alzheimer's Drug", which is of great help to medical research and medical research.

As one of the leading scientists, Geng Meiyu's representative publications mainly include "Glycosylation of N-phenyl trifluoroacetylimide sialate and phenynynylate as donors" and "Preclinical study of the new anti-Alzheimer's disease drug HSH-971".

As a teaching and research worker, her representative publications include "Preclinical Study of HSH-971, a New Anti-Alzheimer's Disease-like Drug" and "Glycosylation of Sialic N-Phenyltrifluoroacetylimide and Phenylalkyne as Donors". These writings of hers are very helpful for medical research in our country.

1.The world's first anti-Alzheimer's disease oligosaccharide drug 971 was developed, and the results were transferred in 2009. In July 2013, the drug completed a phase II clinical study of 255 patients with mild to moderate AD.

The results showed that 971** was safe and well tolerated for 6 months, and the overall improvement rate of cognitive dysfunction was reached. At present, the drug has started phase III clinical research and is expected to obtain a new drug certificate in 2016.

2.It is the first in China to establish a screening and systematic pharmacodynamic evaluation platform for anti-tumor drugs targeting receptor tyrosine kinases C-MET, ALK and FGFR that integrates molecules, cells and whole animals in line with international standards. Up to now, several candidate compounds targeting C-Met, ALK and FGFR (ORG BIOMOL CHEM 2013, J MED CHEM 2012, J MED CHEM 2011, CHEM EUR J 2011) with in-depth research value have been obtained, and more than 10 patents have been applied.

Among them, two targeted anti-tumor drugs SIMM244 and SAF189 are undergoing systematic preclinical studies.

3.The second heparanase inhibitor JG3 (Cancer Res 2006) in the world was developed, and its anti-tumor activity was better than that of the first inhibitor PI88 in all aspects. On this basis, further studies have proved that the same series of compounds JG6 can target the filamentin cofilin, thereby inhibiting tumor metastasis, which opens up a new path for the development of anti-tumor metastasis drugs targeting cofilin (Oncotarget 2014).

4.PIGR was found to be an important marker of early** metastasis of liver cancer. Pigr was found to promote the early stage and metastasis of liver cancer by inducing the occurrence of epithelial cell mesenchymal transition (EMT) (J Natl Cancer Inst 2011;am j gastroenterol 2006）。

This study challenges the limitations of the traditional function of pigr, lays an important theoretical foundation for redefining the "non-canonical function" of the immunoglobulin receptor family, and provides the first important paradigm for the study of the duality of immune defense and immune betrayal of immunoglobulin receptors (reviewed by J Natl Cancer INST in the same period). The new function of polyimmunoglobulin receptor pigr immune betrayal was revealed, and it was proved that pigr is an important marker in the early stage of liver cancer.

Targeted receptor tyrosine kinases C-MET, ALK, FGFR anti-tumor drug development and biomarker discovery; anti-tumor studies targeting tumor metabolism; Tumor microenvironment and tumor development and drug resistance.